BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Mostrar otras versiones (1)

BACKGROUND: Breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary treatment of numerous women. B-cell lymphoma 2 (BCL2), an antiapoptotic protein, has been proposed as a prognostic marker, but this effect is considered to relate to oes...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938244/
https://www.ncbi.nlm.nih.gov/pubmed/20664598
http://dx.doi.org/10.1038/sj.bjc.6605736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938244/
https://www.ncbi.nlm.nih.gov/pubmed/20664598
http://dx.doi.org/10.1038/sj.bjc.6605736

Ejemplares similares